Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Completed · Phase 3

Conditions studied: Severe Hemophilia B

In brief

The primary objectives of the study were: to evaluate the safety and tolerability of rFIXFc; to evaluate the efficacy of rFIXFc in all treatment arms; to evaluate the effectiveness of prophylaxis over on-demand (episodic) therapy by comparing the annualized number of bleeding episodes between participants receiving rFIXFc on each prevention (prophylaxis) regimen and participants receiving rFIXFc on an episodic regimen. The secondary objectives of the study were: to evaluate and assess the pharmacokinetic (PK) parameter estimates of rFIXFc and rFIX (BeneFIX®) at baseline in the Sequential PK subgroup as well as rFIXFc at Week 26 (±1 week); to evaluate participants' response to treatment; to evaluate rFIXFc consumption.

Key facts

Study ID

NCT01027364

Run by

Bioverativ Therapeutics Inc.

People needed

123

Starts

2009-12-01

Expected to finish

2012-07-01

Last updated by the study team

2020-12-19

Who can join

Age: 12 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male and 12 years of age and older and weigh at least 40 kg
• Diagnosed with hemophilia B (baseline Factor IX level less than or equal to 2%)
• History of at least 100 exposure days to any Factor IX product
• Platelet count ≥100,000 cells/μL

You may not qualify if…

• History of Factor IX inhibitors
• Kidney or liver dysfunction
• Diagnosed with another coagulation defect other than hemophilia B
• Prior history of anaphylaxis associated with any Factor IX or intravenous (IV) immunoglobulin administration

Where it is running

• Research Site — Sacramento, California, United States
• Research Site — Aurora, Colorado, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Indianapolis, Indiana, United States
• Research Site — East Lansing, Michigan, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Pittsburgh, Pennsylvania, United States
• Research Site — Seattle, Washington, United States
• Research Site — Camperdown, New South Wales, Australia
• Research Site — Adelaide, South Australia, Australia
• Research Site — Perth, Western Australia, Australia
• Research Site — Brussels, Belgium
• Research Site — Leuven, Belgium
• Research Site — Campinas, Brazil
• Research Site — Calgary, Alberta, Canada
• Research Site — Toronto, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Vancouver, Canada
• Research site — Beijing, China
• Research Site — Guangzhou, China
• Research Site — Shanghai, China
• Research Site — Tianjin, China
• Research Site — Lyon, France
• Research Site — Marseille, France
• Research Site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.